Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON - Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening - by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and ...
By Julie Steenhuysen NEW YORK (Reuters) - Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid ...
Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer's experts told Reuters. The two drugs – Leqembi, from partner biotech firms Eisai and Biogen, and an experimental treatment developed by Eli Lilly, donanemab - are the first to offer real hope of slowing the fatal disease for the 6.5 million Americans living with Alzheimer's. Although older Black Americans have twice the rate of dementi...
Researchers revealed that older Black Americans, who have twice the rate of dementia compared to whites were excluded from clinical trials of these drugs
Scientists say while these drugs may mark a new era in Alzheimer's therapy, huge questions remain about which patients should try them and how much benefit they'll really notice.